Working... Menu
Trial record 10 of 30 for:    IGFBP2

Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery (CONTROL-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01360918
Recruitment Status : Terminated (Inclusion rate insufficiënt)
First Posted : May 26, 2011
Last Update Posted : July 7, 2016
Cardio Research Enschede BV
Information provided by (Responsible Party):
B. Oude Velthuis, Medisch Spectrum Twente

Brief Summary:
Recent studies demonstrated that radiofrequency isolation of the pulmonary veins (PVI) is a superior alternative to antiarrhythmic drug therapy in patients with symptomatical paroxysmal atrial fibrillation (AF). A substantial proportion of patients undergoing elective cardiac surgery also suffer from atrial fibrillation. No evidence exists if epicardial PVI is beneficial in patients with a history of AF undergoing coronary bypass surgery (CABG) for the concomitant treatment of AF. The investigators aim to establish the effectiveness of incorporating epicardial pulmonary vein isolation into elective cardiac surgery.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Device: Epicardial pulmonary vein isolation Other: Usual care Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Concomitant Epicardial Pulmonary Vein Isolation in Patients With Atrial Fibrillation Undergoing Elective Cardiac Surgery
Study Start Date : May 2011
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Usual care Other: Usual care
Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.

Active Comparator: Pulmonary vein isolation Device: Epicardial pulmonary vein isolation
After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
Other Name: Medtronic Cardioblate BP2

Primary Outcome Measures :
  1. Recurrence of atrial fibrillation [ Time Frame: one year ]
    The percentage of patients without a recurrence of AF, without antiarrhythmic drugs (AADs), within a follow-up period of at least 12 months after a stabilisation period of 90 days after the initial procedure. An episode of AF is defined as an episode of at least 30 seconds duration.

Secondary Outcome Measures :
  1. Duration of hospitalization [ Time Frame: One year ]
    Secondary objectives include the duration of hospitalization

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ≥ 18 years of age
  • EHRA class ≤ 2
  • Documented history of paroxysmal, persistent, longstanding persistent or newly-diagnosed AF prior to admittance for cardiac surgery
  • Patients will have elective coronary surgery planned Able of providing informed consent

Exclusion Criteria:

  • Patients ≥70 years of age
  • Pregnancy Patients with contraindications for oral anticoagulant agents
  • Patients undergoing emergency operation
  • Patients undergoing concomitant valve replacement
  • Severely enlarged LA (>50 mm) on echocardiography
  • Prior AF ablation or AF surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01360918

Layout table for location information
Medisch Spectrum Twente
Enschede, Overijssel, Netherlands
Sponsors and Collaborators
Medisch Spectrum Twente
Cardio Research Enschede BV
Layout table for investigator information
Principal Investigator: Marcoen Scholten, MD PhD Medisch Spectrum Twente

Layout table for additonal information
Responsible Party: B. Oude Velthuis, B. Oude Velthuis MD., Medisch Spectrum Twente Identifier: NCT01360918     History of Changes
Other Study ID Numbers: NL35192.044.11
First Posted: May 26, 2011    Key Record Dates
Last Update Posted: July 7, 2016
Last Verified: July 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes